Nasdaq
$36.54▲ 0.14%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $26.28BShares out 7.200M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
64- 2d agoAfter-hours26.10.23 07:444Ownership#●●●
Roivant Sciences Ltd.
Eric Venker, an executive at Roivant Sciences Ltd., reported a change in beneficial ownership of securities effective October 20, 2026. This filing serves as a standard Form 4 disclosure regarding insider stock transactions.…more
$36.54+0.14%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 4d agoPre-market26.10.21 20:058-KKey event
Roivant Sciences Ltd.
Roivant Sciences' subsidiary, Priovant Therapeutics, announced that the Phase 3 CLARITY program for its non-infectious uveitis (NIU) treatment, brepocitinib, met all primary and key secondary endpoints with statistically significant results. Based on these successful clinical outcomes, the company intends to file a supplemental New Drug Application (sNDA) with the FDA in the first half of 2027.…more
$36.54+0.14%vs prev closeView filingShare - 4d agoAfter-hours26.10.21 06:424Ownership
Roivant Sciences Ltd.
Roivant Sciences Ltd. insider Mayukh Sukhatme reported a change in beneficial ownership of company securities as of October 16, 2026. This filing serves as a standard disclosure regarding the executive's change in share holdings.…more
$36.54+0.14%vs prev closeView filingShare
63 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 3d agoRegular26.10.22 02:14Bullish#●●●#●●●#●●●
Roivant Sciences Reports Positive Phase 3 Results for Uveitis Drug
Roivant Sciences announced that its investigational therapy brepocitinib met all primary and secondary endpoints in two Phase 3 trials for noninfectious uveitis. The company plans to submit a supplemental New Drug Application in the first half of 2027.…more
$36.54+0.14%vs prev closeDetected5m · 30m · 60m · Next dayPLUSShareBenzinga
- 4d agoPre-market26.10.21 20:00
●●●●●●●● ●●●●● ●●●●●●
Roivant's brepocitinib met all primary and key secondary endpoints in its Phase 3 trials for non-infectious uveitis with statistically significant results. The company plans to file a supplemental New Drug Application in the first half of 2027.…more
$36.54+0.14%vs prev close - 9.23Pre-market26.09.23 22:03
●●●●●●●● ●●●●● ●●●●●●
Immunovant has decided to discontinue the development of IMVT-1402 for cutaneous lupus erythematosus after the drug failed to meet its primary endpoint in a clinical trial. The company will now shift its focus toward advancing the drug for other autoimmune conditions.…more
$36.54+0.14%vs prev closeShareBenzinga
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report